Aptose Biosciences Auditor KPMG Not Re-Appointed

Aptose Biosciences ( (TSE:APS) ) has provided an announcement.

On April 23, 2025, Aptose Biosciences announced that its current auditor, KPMG LLP, will not stand for re-appointment for the company’s 2025 annual audit. KPMG will continue to review the company’s quarterly interim financial results through the first two fiscal quarters of 2025. The decision was made independently by KPMG without the involvement of Aptose’s Board of Directors or Audit Committee. Despite this change, there were no disagreements or reportable events between Aptose and KPMG during the fiscal years ending December 31, 2024, and 2023, except for a communicated material weakness in internal control over financial reporting.

Spark’s Take on TSE:APS Stock

According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.

Aptose Biosciences’ financial struggles are significant, with no revenue and considerable losses weighing heavily on its overall score. However, positive corporate developments in AML therapy offer some hope for future growth and funding. Technical indicators suggest a bearish market sentiment, while valuation metrics reflect ongoing challenges with profitability.

To see Spark’s full report on TSE:APS stock, click here.

More about Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. The company’s pipeline includes small molecule cancer therapeutics designed to enhance the efficacy of other anti-cancer therapies without overlapping toxicities. Its lead compound, tuspetinib (TUS), is an oral kinase inhibitor being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML).

YTD Price Performance: -65.83%

Average Trading Volume: 225,274

Technical Sentiment Signal: Strong Buy

Current Market Cap: $6.05M

For a thorough assessment of APS stock, go to TipRanks’ Stock Analysis page.